Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kamal Mroue"'
Autor:
Ahmed Abotaleb, Ivan Gladich, Kamal Mroue, Nada Abounahia, Alaa Alkhateeb, Abdulaziz Al-Shammari, Yongfeng Tong, Dema Al-Masri, Alessandro Sinopoli
Publikováno v:
Heliyon, Vol 10, Iss 21, Pp e39952- (2024)
Halloysite nanotubes (HNTs) are naturally occurring aluminosilicate minerals, known for their unique tubular structure, which have garnered significant interest for a wide range of applications. This study explores the morphological changes of HNTs w
Externí odkaz:
https://doaj.org/article/ab7ab4b258464096bd77231398d2f339
Autor:
Mohamed H. M. Ali, Salman M Toor, Fazle Rakib, Raghvendra Mall, Ehsan Ullah, Kamal Mroue, Prasanna R. Kolatkar, Khalid Al-Saad, Eyad Elkord
Publikováno v:
Vaccines, Vol 7, Iss 3, p 109 (2019)
Interactions between programmed death-1 (PD-1) with its ligand PD-L1 on tumor cells can antagonize T cell responses. Inhibiting these interactions using immune checkpoint inhibitors has shown promise in cancer immunotherapy. MDA-MB-231 is a triple ne
Externí odkaz:
https://doaj.org/article/dab869c910a84b7b9b332acfc19b6b5a
Autor:
Ismail W. Almanassra, Yahya Zakaria, Viktor Kochkodan, Kamal Mroue, Atef Zekri, Muataz Ali Atieh, Tareq Al-Ansari
In this study, the stability, thermal conductivity and viscosity of carbide-derived carbon antifreeze thermal fluids were explored. The study also compares the results between antifreeze suspensions prepared using oxidized CDC and emulsified CDC usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1167e83a549d6f0f946878c4c3992e09
Autor:
Eyad Elkord, Salman M Toor, Mohamed H. M. Ali, Ehsan Ullah, Khalid Al-Saad, Prasanna R. Kolatkar, Kamal Mroue, Fazle Rakib, Raghvendra Mall
Publikováno v:
Vaccines, Vol 7, Iss 3, p 109 (2019)
Vaccines
Volume 7
Issue 3
Vaccines
Volume 7
Issue 3
Interactions between programmed death-1 (PD-1) with its ligand PD-L1 on tumor cells can antagonize T cell responses. Inhibiting these interactions using immune checkpoint inhibitors has shown promise in cancer immunotherapy. MDA-MB-231 is a triple ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f1aa38b120a25fb078137a180a28077
https://hdl.handle.net/10576/14389
https://hdl.handle.net/10576/14389